In Vitro Activities of Amoxicillin-Clavulanate, Doxycycline, Ceftazidime, Imipenem, and Trimethoprim-Sulfamethoxazole against Biofilm of Brazilian Strains of *Burkholderia pseudomallei*

Tereza de Jesus Pinheiro Gomes Bandeira,^{a,c,e} Camila Alencar Moreira,^c Raimunda Sâmia Nogueira Brilhante,^{a,b,c} Débora de Souza Collares Maia Castelo-Branco,^{a,c} Manoel Paiva de Araújo Neto,^{a,d} Rossana de Aguiar Cordeiro,^{a,b,c} Terezinha de Jesus Santos Rodrigues,^{a,c} Marcos Fábio Gadelha Rocha,^{a,c,d} José Júlio Costa Sidrim^{a,b,c}

Specialized Medical Mycology Center, Federal University of Ceará, Fortaleza, Ceará, Brazil^a; Postgraduate Program in Medical Sciences, Federal University of Ceará, Fortaleza, Ceará, Brazil^b; Postgraduate Program in Medical Microbiology, Federal University of Ceará, Fortaleza, Ceará, Brazil^c; Postgraduate Program in Veterinary Science, State University of Ceará, Fortaleza, Ceará, Brazil^d; LabPasteur—DASA, Ceará, Brazil^e

This study aimed at investigating the *in vitro* activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against *Burkholderia pseudomallei* in planktonic and biofilm forms, through broth microdilution and resazurin-based viability staining, respectively. In planktonic growth, the strains were susceptible to the drugs, while in biofilm growth, significantly higher antimicrobial concentrations were required, especially for ceftazidime and imipenem, surpassing the resistance breakpoints. These results highlight the importance of the routine evaluation of biofilm antimicrobial susceptibility.

Burkholderia pseudomallei is the causative agent of melioidosis, a disease endemic to southeastern Asia, northern Australia, and northeastern Brazil, that presents high lethality rates (1, 2, 3). Currently, the most commonly used antimicrobials for treating melioidosis are ceftazidime (CAZ), imipenem (IPM), amoxicillin-clavulanate (AMC), doxycycline (DOX), and trimethoprim-sulfamethoxazole (SXT) (2–4), but there have been several reports of *in vitro* and *in vivo* resistance to these drugs among *B. pseudomallei* isolates (1–3). This resistance may be related to biofilm-associated *B. pseudomallei* infections (5–7), which emphasizes the importance of treating melioidosis with antimicrobials that are effective against *B. pseudomallei* biofilms. Thus, the aim of this study was to assess the *in vitro* activities of the five commonly used antimicrobial drugs in the treatment of melioidosis against strains of *B. pseudomallei* in planktonic form and in biofilm form.

Nine strains of β -lactamase-positive *B. pseudomallei*, isolated from clinical and environmental sources and stored at the Laboratory of Emerging and Reemerging Pathogens of the Federal University of Ceará, Brazil, were used in this study (4). *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, methicillin-resistant *Staphylococcus aureus* (MRSA), *Staphylococcus aureus* ATCC 25923 (a biofilm producer), and non-biofilm-producing *Staphylococcus epidermidis* were used as experimental controls.

The ability of each strain to produce biofilm was quantified spectrophotometrically as previously described (8, 9). Biofilm production was induced in a flat-bottomed well of a 96-well microtiter plate, using brain heart infusion broth (Oxoid, Basingstoke, Hampshire, England) enriched with 1% glucose. The plates were incubated for 48 h at 37°C (8, 9), and each well was dyed with 0.25% crystal violet, after washing with phosphate-buffered saline (PBS). Based on the obtained optical density values at 570 nm (OD₅₇₀), the strains were classified as nonproducers, weak producers, moderate producers, or strong producers, as described by Stepanovic et al. (8).

Susceptibility testing was performed through broth microdilution with AMC, CAZ, DOX, IPM, and SXT (Sigma-Aldrich, Brazil) (4), as standardized by the Clinical and Laboratory Standards

Institute (CLSI) and described in document M07-A8 (10). Plates were incubated at 37°C for 24 h, and MICs were defined as the lowest concentrations able to inhibit 100% of growth (10).

Minimum biofilm-inhibitory concentrations (MBICs) and minimum biofilm elimination concentrations (MBECs) were determined by the broth microdilution method with the use of resazurin (Sigma-Aldrich, Brazil). Briefly, 2-day adherent *B. pseudomallei* biofilms were grown in wells as previously described (8, 9). Then, the wells were washed with PBS, and each antimicrobial drug was added in progressive 2-fold dilutions (11). The antimicrobial concentration ranges were: 4/2 to 512/256, 4 to 512, 0.5 to 64, 2 to 256, and 0.5/9.5 to 64/1,216 mg/liter for AMC, CAZ, DOX, IPM, and SXT, respectively. Plates were incubated at 37°C for 24 h. Then, 20 μ l of 0.05% resazurin solution was added, and plates were incubated for 1 h (12–14). The MBIC was defined as the lowest concentration able to partially inhibit cellular activity, while the MBEC was defined as the lowest concentration with no evidence of cellular activity (15, 16).

The tests were performed in triplicate and repeated on two different occasions. Student's *t* test was employed to evaluate the obtained data. Differences were considered statistically significant when *P* was <0.05.

The obtained cutoff for biofilm production was 0.021, and the tested strains were classified as weak (*n* = 1), moderate (*n* = 3), or strong (*n* = 5) producers (Table 1).

The following MIC ranges were observed: 4/2 to 16/8, 2 to 8, 0.25 to 0.5, 0.125 to 1, and 0.125/2.375 to 2/38 mg/liter for AMC,

Received 9 April 2013 Returned for modification 17 June 2013

Accepted 24 August 2013

Published ahead of print 3 September 2013

Address correspondence to Raimunda Sâmia Nogueira Brilhante, brilhante@ufc.br.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.00721-13

TABLE 1 Biofilm-producing abilities of nine *B. pseudomallei* isolates^a

Strain designation, OD ₅₇₀ value		
Weak biofilm producer (OD ₅₇₀ , 0.021 to 0.043)	Moderate biofilm producers (OD ₅₇₀ , 0.043 to 0.085)	Strong biofilm producers (OD ₅₇₀ , >0.085)
Bp096c, 0.023 ^b	Bp038c, 0.052 Bp041e, 0.076 Bp044e, 0.066	Bp011c, 0.153 Bp040e, 0.238 Bp043e, 0.128 Bp045e, 0.195 Bp066c, 0.105

^a Isolate designations ending with a c were obtained from a clinical source; those ending with an e were obtained from an environmental source.
^b The average OD₅₇₀.

CAZ, DOX, IPM, and SXT, respectively. All tested *B. pseudomallei* strains were susceptible to the five antimicrobials (17) (Table 2).

MBIC and MBEC values were often the same, and the obtained MBIC/MBEC ranges were 8/4 to 64/32, 4 to <512, 1 to 8, >256, and 0.5/9.5 to 2/38 mg/liter for AMC, CAZ, DOX, IPM, and SXT, respectively. The mean inhibitory concentrations of the five tested antimicrobial agents against mature *B. pseudomallei* biofilms were higher than the obtained MICs (Table 2), especially the MBICs and MBECs for IPM ($P < 0.001$) and the MBICs for CAZ ($P < 0.001$). Many of the MBIC/MBEC values surpassed the resistance breakpoints (17), especially those for IPM, turning all strains resistant to this drug.

Biofilms are commonly associated with the occurrence of recalcitrant infections (18) and are notorious for their ability to tolerate high concentrations of antibiotics that are lethal to their planktonic counterparts (6). In general, our results showed significantly higher antimicrobial inhibitory concentrations against *B. pseudomallei* biofilms, as previously reported (5, 7), especially for β -lactams, reaching values above the resistance breakpoints. No correlation was observed between the ability to form biofilm and the antimicrobial susceptibility of each strain. Instead, biofilm susceptibility seemed to be related to the chemical characteristics of the antimicrobial. DOX and SXT, for example, showed the best inhibitory and bactericidal activities, with MBIC/MBEC values below resistance breakpoints, while *B. pseudomallei* biofilms were resistant to CAZ and IPM, which resulted in significantly higher MBIC and MBIC/MBEC values, respectively.

This resistance to CAZ and IPM may rely on a few possibilities: (i) decreased drug diffusion through the structures of *B. pseudomallei* biofilms (7); (ii) low growth rates of biofilm cells, since these drugs primarily target fast-growing bacteria (5, 7); (iii) the secretion of β -lactamases, as this is one of the main mechanisms of β -lactam resistance in *B. pseudomallei* (19, 20); and (iv) the development of persister cells (18), even though these are dormant cells with basal protein production (18) and thus low β -lactamase production, which most likely do not produce sufficient β -lactamase to hydrolyze and neutralize antibiotic molecules.

It has been shown that in biofilms of *Pseudomonas aeruginosa*, β -lactamases are secreted and maintain their activity within the biofilm matrix, and these enzymes hydrolyze β -lactam antibiotics before reaching the bacterial cells (6). In addition, the production of β -lactamases by biofilm cells can be induced by β -lactam antibiotics, such as CAZ and IPM, which increase the levels of free β -lactamases within the biofilm matrix (6). We strongly believe that a similar mechanism occurs in biofilms of *B. pseudomallei*.

TABLE 2 Susceptibilities to five antimicrobial agents of *B. pseudomallei* isolates in planktonic and biofilm forms

MIC, MBIC, and MBEC (mg/liter) for isolate in indicated biofilm-producing group (fold change ^d)											
Drug	Parameter	Weak producer			Moderate producer			Strong producer			Mean fold change ^b
		Bp096	Bp038	Bp041	Bp044	Bp011	Bp040	Bp043	Bp045	Bp066	
AMC	MIC	8/4	16/8	8/4	4/2	16/8	8/4	16/8	8/4	8/4	3
	MBIC	64/32 (8, R)	8/4 (0.5, S)	8/4 (1, S)	8/4 (2, S)	64/32 (4, R)	8/4 (1, S)	8/4 (0.5, S)	8/4 (1, S)	16/8 (2, S)	
	MBEC	64/32 (8, R)	16/8 (1, S)	16/8 (2, S)	16/8 (4, S)	64/32 (4, R)	8/4 (1, S)	16/8 (1, S)	8/4 (1, S)	32/16 (4, R)	
	MIC	8	4	4	2	8	4	8	4	8	
CAZ	MBIC	>512 (>64, R)	8 (2, S)	16 (4, S)	4 (2, S)	>512 (>64, R)	8 (2, S)	16 (2, S)	4 (1, S)	4 (0.5, S)	>18
	MBEC	>512 (>64, R)	64 (16, R)	>512 (>128, R)	>512 (>256, R)	>512 (>64, R)	128 (32, R)	>512 (>64, R)	>512 (>128, R)	>512 (>64, R)	
	MIC	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.5	0.25	
	MBIC	1 (4, S)	1 (4, S)	1 (4, S)	2 (8, S)	1 (4, S)	1 (4, S)	2 (8, S)	1 (4, S)	2 (8, S)	
DOX	MBEC	2 (8, S)	2 (8, S)	4 (16, S)	8 (32, S)	2 (8, S)	2 (8, S)	4 (16, S)	8 (16, S)	2 (8, S)	5**
	MIC	0.5	1	1	0.5	0.125	0.5	0.25	1	0.5	
	MBIC	>256 (>512, R)	>256 (>256, R)	>256 (>256, R)	>256 (>512, R)	256 (2,048, R)	>256 (>512, R)	256 (>512, R)	>256 (>256, R)	>256 (>512, R)	
	MBEC	>256 (>512, R)	>256 (>256, R)	>256 (>256, R)	>256 (>512, R)	>256 (>2,048, R)	>256 (>512, R)	>256 (>1,024, R)	>256 (>256, R)	>256 (>512, R)	
IPM	Fold ratio ^a										>654**
	MIC	0.25/4.75	0.5/9.5	2/38	0.125/2.375	0.5/9.5	0.25/4.75	2/38	0.25/4.75	0.25/4.75	
	MBIC	$\leq 0.5/9.5$ (≤ 2 , S)	$\leq 0.5/9.5$ (≤ 1 , S)	$\leq 0.5/9.5$ (≤ 1 , S)	$\leq 0.5/9.5$ (≤ 4 , S)	$\leq 0.5/9.5$ (≤ 1 , S)	$\leq 0.5/9.5$ (≤ 2 , S)	$\leq 0.5/9.5$ (≤ 2 , S)	$\leq 0.5/9.5$ (≤ 2 , S)	$\leq 0.5/9.5$ (≤ 2 , S)	
	MBEC	$\leq 0.5/9.5$ (≤ 2 , S)	$\leq 0.5/9.5$ (≤ 1 , S)	2/38 (≤ 1 , S)	$\leq 0.5/9.5$ (≤ 4 , S)	$\leq 0.5/9.5$ (≤ 1 , S)	$\leq 0.5/9.5$ (≤ 2 , S)	2/38 (≤ 1 , S)	1/19 (4, S)	$\leq 0.5/9.5$ (≤ 2 , S)	

^a The fold change compared to the MIC. R, resistant; S, susceptible.
^b *, $P < 0.05$; **, $P < 0.001$.

The results of the present study point to the need for standardizing routine methods to evaluate biofilm antimicrobial susceptibility. Nowadays, it is a common belief that more studies should be focused on biofilm rather than planktonic growth in order to succeed in controlling bacterial infections.

ACKNOWLEDGMENTS

This work was supported by CAPES/Brazil (PNPD 2103/2009; AE10052000630100/11) and by Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico and the National Council for Scientific and Technological Development (PPSUS FUNCAP/CNPq, Brazil, process 13192409-5).

REFERENCES

1. Limmathurotsakul D, Peacock SJ. 2011. Melioidosis: a clinical overview. *Br. Med. Bull.* 99:125–139.
2. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. *Clin. Microbiol. Rev.* 18:383–416.
3. White NJ. 2003. Melioidosis. *Lancet* 361:1715–1722.
4. Brilhante RSN, Valente LGA, Rocha MFG, Bandeira TJPG, Cordeiro RA, Lima RAC, Leite JGG, Ribeiro JF, Pereira JF, Castelo-Branco DSCM, Monteiro AG, Sidrim JJC. 2012. Sesquiterpene farnesol contributes to increased susceptibility to β -lactams in strains of *Burkholderia pseudomallei*. *Antimicrob. Agents Chemother.* 56:2198–2200.
5. Sawasdidoln C, Taweekaisupapong S, Sermswan RW, Tattawasart U, Tungpradabkul S, Wongratanacheewin S. 2010. Growing *Burkholderia pseudomallei* in biofilm stimulating conditions significantly induces antimicrobial resistance. *PLoS One* 5(2):e9196. doi:10.1371/journal.pone.0009196.
6. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. *Int. J. Antimicrob. Agents* 35:322–332.
7. Pibulpakdee P, Wongratanacheewin S, Taweekaisupapong S, Niumsup PR. 2012. Diffusion and activity of antibiotics against *Burkholderia pseudomallei* biofilms. *Int. J. Antimicrob. Agents* 39:356–359.
8. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *J. Microbiol. Methods* 49:175–179.
9. Moreira CA, Oliveira LC, Mendes MS, Santiago TM, Barros EB, Carvalho CBM. 2012. Biofilm production by clinical Staphylococci strains from canine otitis. *Braz. J. Microbiol.* 43:371–374.
10. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard. CLSI document M07-A8. CLSI, Wayne, PA.
11. Roveta S, Schito AM, Marchese A, Schito GC. 2007. Activity of moxifloxacin on biofilms produced *in vitro* by bacterial pathogens involved in acute exacerbations of chronic bronchitis. *Int. J. Antimicrob. Agents* 30:415–421.
12. Peeters E, Nelis HJ, Coenye T. 2008. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. *J. Microbiol. Methods* 72:157–165.
13. Pettit RK, Weber CA, Kean MJ, Hoffman H, Pettit GR, Tan R, Franks KS, Horton ML. 2005. Microplate alamar blue assay for *Staphylococcus epidermidis* biofilm susceptibility testing. *Antimicrob. Agents Chemother.* 49:2612–2617.
14. Toté K, Vanden Berghe D, Maes L, Cos P. 2008. A new colorimetric microtitre model for the detection of *Staphylococcus aureus* biofilms. *Lett. Appl. Microbiol.* 46:249–254.
15. Sarker SD, Nahar L, Kumrasamy Y. 2007. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the *in vitro* antibacterial screening of phytochemicals. *Methods* 42:321–324.
16. Sandberg ME, Schellmann D, Brunhofer G, Erker T, Busygin I, Leino R, Vuorela PM, Fallarero A. 2009. Pros and cons of using resazurin staining for quantification of viable *Staphylococcus aureus* biofilm in a screening assay. *J. Microbiol. Methods* 78:104–106.
17. Clinical and Laboratory Standards Institute. 2010. Methods for antimicrobial dilution and disk susceptibility tests of infrequently isolated or fastidious bacteria. Approved guideline. CLSI document M45-A2, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Kwan BW, Valenta JA, Benedik MJ, Wood TK. 2013. Arrested protein synthesis increases persister-like cell formation. *Antimicrob. Agents Chemother.* 57:1468–1473.
19. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer HP. 2011. Molecular investigations of PenA-mediated β -lactam resistance in *Burkholderia pseudomallei*. *Front. Microbiol.* 2:139. doi:10.3389/fmicb.2011.00139.
20. Schweizer HP. 2012. Mechanisms of antibiotic resistance in *Burkholderia pseudomallei*: implications for treatment of melioidosis. *Future Microbiol.* 7:1389–1399.